Evidence map›Paper›PMID 33715993›Full record

Trial reportJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2022

Health care costs related to home spirometry in the eICE randomized trial.

Natalie Franz, Hannah Rapp, Ryan N Hansen, Laura S Gold, Christopher H Goss, Noah Lechtzin, Larry G Kessler

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 3 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 3 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Symptom phenotyping in people with cystic fibrosis during acute pulmonary exacerbations using machine-learning K-means clustering analysis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Natalie FranzDepartment of Health Services, University of Washington, Seattle, Washington, United States.
Hannah RappDepartment of Health Services, University of Washington, Seattle, Washington, United States.
Ryan N HansenSchool of Pharmacy, University of Washington, Seattle, Washington, United States.
Laura S GoldDepartment of Radiology, University of Washington, Seattle, Washington, United States.
Christopher H GossDepartment of Medicine, University of Washington, Seattle, Washington, United States; Department of Pediatrics, University of Washington, Seattle, Washington, United States.
Noah LechtzinDepartment of Medicine, Johns Hopkins University, Baltimore, Maryland, United States.
Larry G KesslerDepartment of Health Services, University of Washington, Seattle, Washington, United States. Electronic address: kesslerl@uw.edu.
University of Washington · USJohns Hopkins University · US

Funding

Institute of Translational Health SciencesUL1TR000423 · NCATS · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2012 to 2016
$49.4M
Translational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Christopher Hooper Goss · 2010 to 2026
$21.4M
Proof of Principle Evaluation of IV Gallium Nitrate in Patients with CFUM1HL119073 · NHLBI · UNIVERSITY OF WASHINGTON · PI GOSS, CHRISTOPHER HOOPER, SINGH, PRADEEP K · 2013 to 2017
$4.8M
A Phase 1b, Multi-center Study of IV Gallium Nitrate in Patients with Cystic Fibrosis who are colonized with Nontuberculosis Mycobacterium (The ABATE Study).R01FD006848 · FDA · SEATTLE CHILDREN'S HOSPITAL · PI Christopher Hooper Goss, JERRY A NICK · 2020 to 2026
$3.1M
Phase 2 Study of Intravenous Gallium Nitrate in the Treatment of Cystic FibrosisR01FD003704 · FDA · UNIVERSITY OF WASHINGTON · PI GOSS, CHRISTOPHER HOOPER · 2009 to 2018
$2.0M
FDA HHS R01 FD003704FDA HHS R01 FD006848NCATS NIH HHS UL1 TR000423NHLBI NIH HHS UM1 HL119073NIDDK NIH HHS P30 DK089507
6 · The paper itself

Abstract

backgroundHome spirometry with regular symptom assessment is one strategy to track lung health to intervene early in episodes of pulmonary exacerbations (PE). In a multi-center randomized controlled trial home spirometry and symptom tracking demonstrated no significant differences regarding the primary clinical endpoint, FEV

methodsWe reviewed healthcare resource utilization of all 267 eICE participants, including outpatient visits, antibiotics and hospitalizations. Prices were identified in the IBM/Watson MarketScan

resultsOutpatient visit costs were significantly higher by 13% in the Early Intervention (EI) than in the usual care (UC) arm ($3,345 vs. $2,966). We found no significant differences in outpatient antibiotic, hospitalization, or total health care costs between the arms.

conclusionsWithin the context of the eICE trial, outpatient visits were significantly higher in those with experimental home spirometry care, but that did not translate into statistically significant differences of overall health care costs between the two arms.

Indexed as

Health Care CostsAdolescentChildCystic FibrosisFemaleHome Care ServicesHumansMalePatient Acceptance of Health CareProspective StudiesRetrospective StudiesSpirometryCystic fibrosisHealthcare cost, Cost effectivenessHome spirometryPulmonary exacerbations

Identifiers

PMID33715993
PMCPMC8433261
OpenAlexW3138182042

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.